Across TCGA pan-cancer cohorts, PCDH9-AS2 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PCDH9-AS2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PCDH9-AS2 RNA is repressed in tumor relative to normal tissue. In most cancer types PCDH9-AS2 is over-expressed in tumor, although a few such as LIHC and KIRC show the opposite, repressed pattern.

LIHC, KIRC, and CHOL are the cancer types where PCDH9-AS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCDH9-AS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	−1.171	<.001	6	view →
KIRC	All	All	−0.016	.004	6	view →
CHOL	All	All	−1.033	<.001	2	view →
STAD	All	All	−0.137	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PCDH9-AS2 RNA expression & survival · all PCDH9-AS2 data types